Pan Canadian Pharmaceutical Alliance

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates   The latest update as of May 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Nine new drug products have initiated pCPA negotiations since the last update, for a total of 43 active negotiations Four negotiations have been completed since the last update, for a total of 153 joint negotiations. No new drug…

Consultations Commence for Major Changes to Canadian Pharmaceutical Policy   On May 16, 2017, the Federal Minister of Health, the Hon. Jane Philpott presented several major announcements, which are likely to have significant impacts on both national and provincial/territorial pharmaceutical policy.  The announcements covered an array of developments including: changes to the regulations that govern how the Patented Medicine Prices Review Board (PMPRB) operates; enhancing the capacity of the pan-Canadian…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of April 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Nine new products have initiated pCPA negotiations since the last update, for a total of 38 active negotiations: Cosentyx (secukinumab) – psoriatic arthritis Cosentyx (secukinumab) – ankylosing spondylitis Erelzi (etanercept) – ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of March 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows: Three new products have initiated pCPA negotiations since the last update, for a total of 30 active negotiations: Afinitor (everolimus) for a new indication - treatment of neuroendocrine tumours of gastrointestinal or lung origin Campral (acamprosate calcium) used…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of February 28, 2017. There are currently 33 negotiations underway with one new file – Eylea (aflibercept) was added since the last update on January 31, 2017. There have been 142 joint negotiations completed with 8 files successfully negotiated since the last update of January 31, 2017: Daklinza…

The pCPA has completed negotiations with 3 manufacturers of drugs used to treat Hepatitis C   The pan-Canadian Pharmaceutical Alliance (pCPA), in its first stand-alone statement, announced on February 21, 2017 that they have successfully negotiated agreements with Gilead, Merck, and Bristol Myers Squibb. There is one notable absence from this list - that of the 4th manufacturer of hepatitis C drugs, Abbvie who manufactures Holkira and Technivie.   These…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of January 31, 2017. There are currently 38 negotiations underway with one new file (Keytruda (pembrolizumab)) added since the last update on December 31, 2016. There have been 133 joint negotiations completed with 2 files successfully negotiated since the last update of December 31, 2016: Blincyto…

The pan-Canadian Pharmaceutical Alliance (pCPA) Office released the monthly statistics for pCPA negotiations up to and including December 31, 2016.   To summarize, there were a total of 7 products with status changes: Three products added to the active list for a total of 43 active negotiations: Botox (multiple indications), Imbruvica (chronic lymphocytic leukemia/small lymphocytic leukemia), Rituxan SC. Two products concluded negotiations with an agreement: Grastofil, Metadol-D. Two products that…